Literature DB >> 11012769

CD28, CTLA-4 and their ligands: who does what and to whom?

D M Sansom1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11012769      PMCID： PMC2327073          DOI： 10.1046/j.1365-2567.2000.00121.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  110 in total

1.  CTLA-4-Mediated inhibition of early events of T cell proliferation.

Authors:  M C Brunner; C A Chambers; F K Chan; J Hanke; A Winoto; J P Allison
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.

Authors:  R Khattri; J A Auger; M D Griffin; A H Sharpe; J A Bluestone
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

3.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.

Authors:  M Itoh; T Takahashi; N Sakaguchi; Y Kuniyasu; J Shimizu; F Otsuka; S Sakaguchi
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

4.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

5.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy.

Authors:  V K Kuchroo; M P Das; J A Brown; A M Ranger; S S Zamvil; R A Sobel; H L Weiner; N Nabavi; L H Glimcher
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

6.  CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.

Authors:  X X Zheng; T G Markees; W W Hancock; Y Li; D L Greiner; X C Li; J P Mordes; M H Sayegh; A A Rossini; T B Strom
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

7.  Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus.

Authors:  M F Liu; J S Li; T H Weng; H Y Lei
Journal:  Scand J Immunol       Date:  1999-01       Impact factor: 3.487

8.  The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.

Authors:  T A Judge; Z Wu; X G Zheng; A H Sharpe; M H Sayegh; L A Turka
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

9.  CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts.

Authors:  C Olsson; K Riesbeck; M Dohlsten; E Michaëlsson; K Riebeck
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

10.  A negative regulatory function of B7 revealed in B7-1 transgenic mice.

Authors:  M P Sethna; L van Parijs; A H Sharpe; A K Abbas; G J Freeman
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745
View more
  91 in total

Review 1.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

3.  Herpes Simplex Virus 1 ICP22 Suppresses CD80 Expression by Murine Dendritic Cells.

Authors:  Harry Matundan; Homayon Ghiasi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 4.  Mechanisms of checkpoint inhibition-induced adverse events.

Authors:  P Urwyler; I Earnshaw; M Bermudez; E Perucha; W Wu; S Ryan; L Mcdonald; S N Karagiannis; L S Taams; N Powell; A Cope; S Papa
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

Review 5.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

6.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

7.  The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.

Authors:  Rathasapa Patarat; Shoji Riku; Pattapon Kunadirek; Natthaya Chuaypen; Pisit Tangkijvanich; Apiwat Mutirangura; Charoenchai Puttipanyalears
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

8.  Lack of T-cell-mediated IL-2 and TNFα production is linked to decreased CD58 expression in intestinal tissue during acute simian immunodeficiency virus infection.

Authors:  Diganta Pan; Arpita Das; Sudesh K Srivastav; Vicki Traina-Dorge; Peter J Didier; Bapi Pahar
Journal:  J Gen Virol       Date:  2018-11-29       Impact factor: 3.891

9.  Differential expression of CTLA-4 among T cell subsets.

Authors:  C B Jago; J Yates; N Olsen Saraiva Câmara; R I Lechler; G Lombardi
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

10.  Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37.

Authors:  Shane C Burgess; T Fred Davison
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.